ME/CFS and Long COVID Clinical Relevancy with Anhydrous Enol-Oxaloacetate (% of Treated Patients that reduced the Chalder Fatigue Bimodal Score to 4 or less) | |
---|---|
ME/CFS 500 mg BID | 21.7% |
ME/CFS 1000 mg BID | 27.6% |
ME/CFS 1000 mg TID | 33.3% |
Long COVID 500 mg BID | 46.8% |
Long COVID 1000 mg BID | 20.7% |